2
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Leukemia, Myeloid, Acute
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Noonan Syndrome 5
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Liver Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Early Hormone Receptor-positive Breast Cancer
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
87
fludarabine
77
fludarabine phosphate
45
Tacrolimus
45
Whole-Body Irradiation
42
Mycophenolic Acid
42
Busulfan
35
Melphalan
32
Antilymphocyte Serum
24
Methotrexate
23
thymoglobulin
22
Standard of Care
22
Rituximab
22
venetoclax
20
Thiotepa
20
Sirolimus
20
Azacitidine
20
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
17
Cytarabine
16
Bortezomib
16
Nivolumab
15
Filgrastim
15
Specimen Handling
14
Dexamethasone
14
Blood Specimen Collection
14
Cyclosporine
13
Surveys and Questionnaires
12
Mesna
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Antineoplastic Agents
×
Clear all
NCT07621289
2026-06-02
EUCARTOXSCORES
University Hospital, Caen
Not yet recruiting
10,000 enrolled